Benralizumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Benralizumab
Monoclonal antibody
Type Whole antibody
Source Humanized (from mouse)
Target CD125
Clinical data
Trade names Fasenra
Routes of
administration
Subcutaneous injection
ATC code
Legal status
Legal status
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
Formula C6492H10060N1724O2028S42
Molar mass 146.0 kg/mol
 ☒N☑Y (what is this?)  (verify)

Benralizumab (INN, trade name Fasenra) is a monoclonal antibody which developed by MedImmune for the treatment of asthma. It is directed against the alpha-chain of the interleukin-5 receptor (CD125).[1][2]

Two Phase 3 clinical trials of benralizumab, SIROCCO and CALIMA, reported meeting their primary endpoints in 2016.[3][4] It was approved by the US FDA in November 2017 for the treatment of severe eosinophilic asthma.[5]

References[edit]

  1. ^ Statement on an Nonproprietary Name adopted by the USAN Counil: Benralizumab
  2. ^ Catley, M. C. (2010). "Asthma & COPD--IQPC's Second Conference". IDrugs : the investigational drugs journal. 13 (9): 601–604. PMID 20799138. 
  3. ^ AstraZeneca's benralizumab reduces asthma exacerbations up to 51% in two late-state studies. Sept 2016
  4. ^ Nair, Parameswaran; Wenzel, Sally; Rabe, Klaus F.; Bourdin, Arnaud; Lugogo, Njira L.; Kuna, Piotr; Barker, Peter; Sproule, Stephanie; Ponnarambil, Sandhia; Goldman, Mitchell (2017). "Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma". New England Journal of Medicine. 376 (25): 2448. doi:10.1056/NEJMoa1703501. PMID 28530840. 
  5. ^ "Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma". AstraZeneca. 2017-11-14.